Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "Results" return 76 results.
ModulDOG Support Page >
The MODULDOG application reminds you to give your dog’s treatment regularly for the best results and helps you assess your dogs skin condition. If you have any feedback please let us know.
World Veterinary Association and Ceva Santé Animale announce the creation of the Global Animal Welfare Awards 2017 >
As global understanding and concern for animal welfare continues to change, so must the veterinary community evolve to embrace these changes and reflect societal expectations.
C.H.I.C.K Program receives the 1st independently audited quality recognition >
For the first time, an AH company services program receives internationally recognized quality approval from Bureau Veritas.
Ceva sponsors the International Symposium on Marek’s Disease and Avian Herpes viruses organised by INRA, France >
11th International Symposium on Marek’s Disease and Avian Herpes viruses organized in Tours, France
Ceva enters Indian market with acquisition of Polchem >
Strong customer technical support will provide a natural platform for the coming together of the 2 businesses.
Ceva reports annual growth of 12% and reaffirms ambition to enter the global top 5 by 2020 >
Raft of new product launches across significant markets powers strong sales in 2015
Ceva posts strong double-digit growth again in H1 2015 >
Libourne 22 nd July 2015 - Consolidated sales of the Ceva Group reached €424m at the end of June 2015, representing growth of 16% and +12% at constant perimeter and exchange rates. Sales grew in all...
Ceva’s new generation Vectormune® AI vaccine proves to be a useful tool to control HPAI >
A paper* recently published in the peer-reviewed journal Vaccine** reports that Ceva’s new generation vaccine, Vectormune® AI, offers significant advantages over previously available vaccines against...
Ceva posts strong double-digit growth again in 2014 >
Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates.